PMID- 15104570
OWN - NLM
STAT- MEDLINE
DCOM- 20040727
LR  - 20151119
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 60
IP  - 5
DP  - 2004 May
TI  - Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
PG  - 644-52
AB  - OBJECTIVE: To determine the interest of Chromogranin A (CgA) determination for 
      diagnosis and follow-up in patients with gastroenteropancreatic endocrine tumours 
      (GEP-ET) and multiple endocrine neoplasia type 1 (MEN-1). PATIENTS AND METHODS: 
      CgA levels were measured with an immunoradiometric assay in 124 sporadic GEP-ET, 
      34 MEN-1 and 127 controls. Serial determinations were performed in 56 patients 
      (212 visits). Changes in CgA levels over 25% were considered as significant. 
      RESULTS: Using a cut-off value of 130 micro g/l, established from a 
      receiver-operating characteristic curve, the specificity of CgA was 98.4%, with a 
      sensitivity of 62.9%, higher in secreting than in nonsecreting tumours (73%vs. 
      45%; P < 0.003) and related to the extent of metastatic spreading (P < 0.001). In 
      nonsecreting tumours, the positive predictive value (PPV) of CgA for the presence 
      of metastases was 100% but the negative predictive value (NPV) was only 50%. In 
      MEN-1, high CgA levels indicated a pancreatic tumour with a 100% specificity but 
      the sensitivity was 59%. During the follow-up, the concordance between CgA and 
      tumour evolution was 80%, whatever the secretory status. In patients with 
      carcinoid tumours, the concordance was higher for CgA than for serotonin (81%vs. 
      54%; P < 0.001). CONCLUSION: Due to its high specificity, CgA determination may 
      help to discriminate the endocrine character of a GEP tumour and to indicate a 
      pancreatic tumour in MEN-1. However, its low NPV in nonsecreting tumours limits 
      its interest for diagnosis and staging. By contrast, serial evaluation of CgA 
      seems of particular interest for the follow-up of GEP-ET tumours.
FAU - Nehar, D
AU  - Nehar D
AD  - Service de Radioanalyse and Centre de Medecine Nucleaire, Hopital 
      Neuro-cardiologique, Hopital Edouard Herriot, Lyon, France.
FAU - Lombard-Bohas, C
AU  - Lombard-Bohas C
FAU - Olivieri, S
AU  - Olivieri S
FAU - Claustrat, B
AU  - Claustrat B
FAU - Chayvialle, J-A
AU  - Chayvialle JA
FAU - Penes, M-C
AU  - Penes MC
FAU - Sassolas, G
AU  - Sassolas G
FAU - Borson-Chazot, F
AU  - Borson-Chazot F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Biomarkers)
RN  - 0 (CHGA protein, human)
RN  - 0 (Chromogranin A)
RN  - 0 (Chromogranins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Chromogranin A
MH  - Chromogranins/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoradiometric Assay/methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/blood/*diagnosis
MH  - Pancreatic Neoplasms/blood/*diagnosis
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Stomach Neoplasms/blood/*diagnosis
EDAT- 2004/04/24 05:00
MHDA- 2004/07/28 05:00
CRDT- 2004/04/24 05:00
PHST- 2004/04/24 05:00 [pubmed]
PHST- 2004/07/28 05:00 [medline]
PHST- 2004/04/24 05:00 [entrez]
AID - CEN2030 [pii]
AID - 10.1111/j.1365-2265.2004.02030.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2004 May;60(5):644-52. doi: 
      10.1111/j.1365-2265.2004.02030.x.